Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Overview of attention for article published in Gastroenterology, March 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
policy: 2 policy sources
twitter: 38 X users
facebook: 1 Facebook page

reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 303 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Adalimumab for Adult Patients with Crohn’s Disease: A Review of Clinical Effectiveness - Adalimumab for Adult Patients with Crohn’s Disease: A Review of Clinical Effectiveness

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 13 May 2020

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Crohn’s disease: management : Post-surgical maintenance of remission

Cited by National Institute for Health and Care Excellence (NICE) on 29 Apr 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.